Zhenliang Fan1,2,3
Puchang Luo4
Yuancheng Gao1,2,3Hongzhen Ma1,2,3Junfen Fan1,2,3Shriya Sanan5
Peipei Zhang1,2,3*†
Keda Lu1,6*†
Hong Xia1,2,5*†- 1Department of Nephrology, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
- 2Zhejiang Key Laboratory of Research and Translation for Kidney Deficiency-Stasis-Turbidity Disease, Hangzhou, Zhejiang, China
- 3Zhejiang-Macau International Joint Laboratory of Integrated Traditional Chinese and Western Medicine for Nephrology and Immunology, Hangzhou, Zhejiang, China
- 4Department of Nephrology, Linping Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, China
- 5Zhejiang Chinese Medical University, Hangzhou, China
- 6Department of Nephrology, the Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
The incidence of Diabetic Kidney Disease (DKD) is rising globally, paralleling the increasing prevalence of diabetes mellitus (DM). As DM spreads worldwide, DKD becomes a significant and growing complication, challenging healthcare systems. DKD is a leading cause of end-stage renal disease (ESRD), requiring costly renal replacement therapies. Mitochondria are vital for cellular energy production via oxidative phosphorylation (OXPHOS), playing a pivotal role in DKD pathogenesis through dysfunction in energy metabolism, reactive oxygen species (ROS) generation, and mitochondrial dynamics. Emerging evidence highlights the crucial role of mitochondrial dysfunction in the pathogenesis and progression of DKD. This review elucidates the intricate relationship between mitochondrial dysfunction and DKD pathophysiology, emphasizing mechanisms such as impaired OXPHOS, excessive ROS production, and disrupted mitochondrial biogenesis. We critically analyze therapeutic interventions, including preclinical compounds, repurposed clinical drugs, and experimental molecules, highlighting their efficacy, limitations, and clinical translation challenges. Emerging evidence suggests novel mitochondrial-targeted therapies may mitigate DKD progression, though controversies, such as inconsistent PGC-1α expression, warrant further investigation. By integrating molecular insights with clinical perspectives, this review aims to guide future research and therapeutic development for DKD.
Introduction
The incidence of DKD is on a steady and concerning rise globally, mirroring the escalating prevalence of diabetes itself. As DM continues its relentless advance across populations worldwide, DKD emerges as a significant and increasingly prevalent complication, presenting a formidable challenge to healthcare systems worldwide. DKD develops in approximately 40% of patients who are diabetic and is the leading cause of CKD worldwide (Alicic et al., 2017). DKD is linked to considerable morbidity and mortality, accounting for 34% of all CKD deaths among men and 36% among women (Ghose et al., 2024). Functioning as the cellular battery unit, mitochondria synthesize adenosine triphosphate (ATP) from ADP via OXPHOS, accounting for more than 90% of the energy production in the human body. OXPHOS, also known as an electron transport-linked metabolic pathway, is dependent on the oxidative reactions that utilize the energy of nutrients to generate ATP through electron transport chain (ETC.) The process needs the help of electron carriers like NADH or FADH2, complex I, II, III, IV, coenzyme Q (CoQ), and cytochrome C (Cyt C).
Mitochondria plays a pivotal role in the control of cellular redox and energy homeostasis, and therefore a major source of intracellular oxidative stress (San-Millán, 2023; Ratliff et al., 2016; Forbes and Thorburn, 2018). Oxidative stress can be classified into two major categories: reactive oxygen species (ROS) and reactive nitrogen species (RNS). ROS are intrinsic to cellular function and are consistently present at low levels in healthy cells. Oxidative stress arises from both unregulated ROS production and inadequate ROS removal by antioxidant systems (Sakashita et al., 2021).
The kidney, a highly metabolic organ, relies on mitochondria for energy-intensive processes such as solute reabsorption, waste elimination, and electrolyte balance, primarily through ATP production via OXPHOS (Bhargava and Schnellmann, 2017). Hence, it is suggested that mitochondrial dysfunction significantly contributes to the development and advancement of kidney disorders, such as DKD (Mise et al., 2020; Wei and Szeto, 2019; Ito et al., 2022).
This review synthesizes the dynamic interplay between mitochondrial dysfunction and DKD, critically evaluating therapeutic strategies and addressing translational challenges to inform clinical practice and future research.
Injury factors to mitochondrial function
Overview of mitochondrial roles
The prominent physiological role of mitochondria is to produce ATP via OXPHOS. Furthermore, mitochondria are involved in bio-processes such as mitochondrial ROS generation, biogenesis, fission, fusion and autophagy (Yang et al., 2024). Any impairment in these processes can lead to mitochondrial dysfunction.
Key mechanisms of mitochondrial injury
Mitochondrial dysfunction in DKD arises from multiple stressors, including hyperglycemia-induced oxidative stress, altered mitochondrial dynamics, and impaired mitophagy. These mechanisms are summarized below to clarify their roles in renal injury (Figure 1).
Figure 1. Factors involved in the pathogenesis of DKD. AGEs, advanced glycation end products; AngII, angiotensin II. Created with BioRender.com.
Mitochondrial dysfunction involved in diabetic nephropathy
Excessive mitochondrial oxidative stress
Altered oxidative phosphorylation
Indicators of OXPHOS function and efficiency encompass oxygen consumption rate (OCR), ATP generation, membrane potential, and the assessment of individual complexes (their activity and formation) (Ito et al., 2022). Typically, it has been noted that OCR in the renal cortex rises during early stages of DKD, subsequently declining as the disease advances. Conversely, OCR in glomeruli and podocytes decreases during both early and late phases of the disease (Mise et al., 2020; Ito et al., 2022). The reduced activation of OXPHOS appears to play a role in DKD, as suggested by findings showing associations between certain genetic mutations in OXPHOS, such as single-nucleotide polymorphisms (SNPs) in coenzyme Q5 (COQ5) and cytochrome c oxidase subunit 6A1 (COX6A1), and DKD in humans (Swan et al., 2015).
Excessive production of ROS
In kidney cells, elevated glucose levels result in heightened activity of protein kinase C (PKC), prompting the production of endothelial nitric oxide synthase (eNOS) and enhancing the NO during the early phases of DKD (Geraldes and King, 2010). Elevated levels of NO stimulates vascular endothelial growth factor (VEGF), ultimately causing impairment in endothelial function (Kanwar et al., 2011). Endothelial cell dysfunction inhibits mitochondrial function and boosts ROS production. ROS are generated as part of the normal functioning of the mitochondrial ETC (mtETC) (Huang et al., 2020). However, when the mtETC malfunctions, there is an excessive production of ROS, leading to oxidative stress and cellular damage in the kidney (Ito et al., 2022).
Various mechanisms: excessive mitochondrial oxidative stress contributing to kidney damage
Mitochondrial oxidative stress contributes to kidney damage through various mechanisms, (Huang et al., 2020), including: (1) Elevated glucose levels activate the c-Jun N-terminal kinase (JNK)- calcium/calmodulin-dependent protein kinase II (CaMKII)- fission factor 1 (FIS1) pathway, leading to mitochondrial fragmentation, heightened production of ROS, and increased activation of JNK. This heightened JNK activity exacerbates podocyte apoptosis and damages renal tubular cells in mice (Zhang Y. et al., 2018) (2) Mitochondrial dysfunction hampers the adenosine monophosphate-activated protein kinase (AMPK)- Sirtuin-1 (SIRT1) - peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) pathway, leading to a decrease in podocyte autophagy. As a result, podocyte damage accumulates, leading to elevated levels of albuminuria (Akhtar and Siragy, 2019) (3) Overproduction of ROS triggers the generation of transforming growth factor-beta (TGF-β), suppresses nitric oxide (NO) levels, and leads to renal fibrosis and damage to endothelial cells (Honda et al., 2019) (4) Excessive ROS hinder mechanistic target of rapamycin complex 1 (mTORC1) and AMPK function, affecting PGC-1α activation. PGC-1α, vital for mitochondrial biogenesis and ROS repair, declines, reducing mtDNA. This leads to decreased mtETC protein synthesis, ROS buildup, and ongoing mtDNA damage, causing kidney impairment (Amorim et al., 2019).
Various mechanisms: excessive mitochondrial oxidative stress contributing to DKD
In DKD, oxidative stress response intertwines with other stress reactions like advanced glycation end-products (AGE) formation and hypoxia. Prolonged hyperglycemia triggers AGE production, inducing oxidative stress by binding to AGE receptors. Mitochondria are known to be susceptible to oxidative damage, and increased levels of ROS, as well as the presence of AGEs, can impair mitochondrial function. This dysfunction can further exacerbate oxidative stress, creating a feedback loop that contributes to the progression of conditions like DKD. Mitochondrial oxidative stress exacerbates the DKD cycle (Ito et al., 2022): (1) High glucose boosts ATP demand, increasing ROS production by mtETC; (2) ROS overproduction damages biomolecules; (3) ROS inhibits mitochondrial growth by downregulating PGC-1α, reducing mtDNA; (4) Diminished mtDNA synthesis impairs electron transport, escalating superoxide generation, further harming mtDNA; (Santos et al., 2011); (5) ROS and impaired mtDNA accumulate over time, resulting in damage to podocytes and renal tubular cells, further worsening renal fibrosis (Huang et al., 2020).
Indirect mechanisms of oxidative stress-induced injury in DKD
Oxidative stress can also induce kidney damage indirectly. For instance, ROS can increase in number by the overexpression of tumor necrosis factor (TNF), but overloaded ROS can drive nuclear factor kappa-B (NF-κ B) downstream signal transduction, which is closely referred to many complications of diabetes (Jha et al., 2016; Jin et al., 2023). Besides, diversified signaling pathways, such as AGE-receptor for advanced glycation end products (RAGE), (Nabi et al., 2023), Kelch-like ECH-associated protein 1(Keap1)- nuclear respiratory factor 2 (NRF2), (Zhu et al., 2021), AMPK/SIRT1, (Gao and Wu, 2022), SIRT1-forkhead transcription factor O (FOXO), (Jalgaonkar et al., 2022), SIRT, (Qiu et al., 2022), and high mobility group box-1 protein (HMGB1) (Jin et al., 2023) could also be induced by oxidative stress (Figure 2). It has been shown that PGC-1α is the key modulator of ROS pathway in the pathogenesis of DKD (Guo et al., 2015; Wu et al., 2015; Al-Kafaji et al., 2016). PGC-1α ameliorates kidney fibrosis in DKD mice by mitigating oxidative stress in podocyte and mesangial cells (Zhang L. et al., 2018).
Figure 2. Key mediators of resident renal cells injury in diabetes nephropathy. The resident renal cells include the podocytes, mesangial cells, endothelial cells and renal tubular epithelial cells. As shown, several possible mechanisms lead to kidney injury implicated in DKD. ROS, reactive oxygen species; Cyt c, Cytochrome c; Apaf-1, apoptotic protease activating factor-1; NF-κB, nuclear factor-kappaB; MCP-1, monocyte chemoattractant protein-1; PKC, protein kinase C; VEGF, vascular endothelial growth factor; Rac1, Ras-related C3 botulinum toxin substrate 1; ERK, extracellular signal-related kinases; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; ADAM17, ADAM metallopeptidase domain 17; ECM, extracellular matrix; PKB, protein kinase B; TRPC6, transient receptor potential cation channel, subfamily C, member 6; EMT, epithelial-mesenchymal transition; ICAM-1, intercellular adhesion molecule 1; TGF- β, transforming growth factor- β; IL-1 β, interleukin-1 β; IL-6, interleukin-6; MAPK, mitogen-activated protein kinase; CTGF, connective tissue growth factor. Created with BioRender.com.
Impaired mitochondrial biogenesis
Altered mitochondrial biogenesis in DKD
Mitochondrial biogenesis is the physiological response to external stimuli to maintain mitochondrial homeostasis (Chen et al., 2022). Mitochondrial biogenesis and dynamics are associated with renal mitochondrial dysfunction and the pathophysiological development of DKD (Song et al., 2022). Cells manage rising energy requirements by boosting mitochondrial biogenesis, a process wherein functional mitochondria are produced through the duplication of mitochondrial DNA (mtDNA) followed by binary fission (Ito et al., 2022). In DKD patients, the enhancement of mitochondrial biogenesis may be a protective to meet the high energy demand in kidney. However, some contrasting studies suggest that mitochondrial biogenesis decreases in diabetic mice (Bugger et al., 2009; Dugan et al., 2013; Coughlan et al., 2016a). A study of the development of rat model in DKD suggested that mitochondrial biogenesis is a common early compensatory event that occurs in conjunction with kidney hyperfiltration and a decline in mitochondrial ATP content but declines following the progression of DKD (Coughlan et al., 2016b).
A pivotal factor - PGC-1α, in the network of mitochondrial biogenesis
Mitochondrial biogenesis is regulated by a variety of factors, much like a network. This multifaceted process comprises a network of therapeutic targets, including upstream sensors and downstream effectors. PGC-1α serves as a pivotal regulator in this intricate network, integrating upstream signals to launch a downstream mitochondrial gene programs facilitating mitochondrial biogenesis (Fernandez-Marcos and Auwerx, 2011). The upstream sensors can activate PGC-1α, including AMPK, SIRT1, calcium/calmodulin-dependent protein kinase IV (CaMKIV), p38 mitogen-activated protein kinase (MAPK), and NO. PGC-1α then regulates mitochondrial biogenesis by modulating various downstream transcription factors, including mitochondrial transcription factor A (TFAM), nuclear respiratory factor 1 (NRF1), NRF2, peroxisome proliferator-activated receptor gamma (PPARγ), estrogen-related receptor α (ERRα) (Ventura-Clapier et al., 2008; Scarpulla, 2011). The transcriptional regulation and post-translational modifications of PGC-1α introduce substantial challenges in considering PGC-1α as a direct target for pharmacological interventions. The network of mitochondrial biogenesis undergoes corresponding changes in a diabetic environment (Figure 3) (Clark and Parikh, 2021)
Figure 3. The regulation of mitochondrial biogenesis and changes affected by diabetic environment. PGC-1α serves as a key regulator of mitochondrial biogenesis. Diabetic environment inhibits PGC-1α by suppressing PGC-1α activators AMPK and SIRT, or suppressing PGC-1α directly. SIRT1, sirtuin 1; AMPK, adenosine monophosphate-activated protein kinase; MAPK, mitogen-activated protein kinase; cAMP, cyclic adenosine monophosphate; PGC-1α, peroxisome proliferator-activated receptor γ coactivator1α; PPARγ, peroxisome proliferator-activated receptor γ; ERRα, estrogen-related receptor α; NRF1/2, nuclear respiratory factor 1/2; TFAM, mitochondrial transcription factor A; mtDNA, mitochondrial DNA. Created with BioRender.com.
Altered PGC-1α in DKD
In DKD, there’s a notable decrease in the expression of PGC-1α within the intrinsic renal cells, triggering a series of harmful consequences. This encompasses diminished mitochondrial biogenesis, increased levels of oxidative stress in mitochondria, disrupted mitochondrial dynamics, and irregular mitophagy. This leads to structural and functional irregularities in the mitochondrial network. Conversely, maintaining high levels of PGC-1α expression proves promising in preserving mitochondrial balance within renal cells, showing significant potential for kidney protection in animal models with DKD (Ye et al., 2024). However, a study by Li et al. showed a heightened PGC1-α expression in the context of DKD, which was concomitant with the occurrence of proteinuria and the spontaneous development of renal pathological alterations (Li et al., 2017). This study leads a noteworthy revelation that the therapeutic efficacy of targeting podocyte PGC1-α in the context of DKD may depend on a specific temporal window. There is the necessity for additional experiments to find out both the efficacy and safety of interventions targeting podocyte PGC1-α level in the context of DKD.
Mitochondrial dynamics abnormalities
What is mitochondrial dynamic?
Mitochondrial dynamics encompasses the processes of fission, fusion, mitophagy, and transport, all of which are essential for maintaining optimal function in signal transduction and metabolism (Chen et al., 2023). Mitochondria are highly motile organelles that undergo carefully regulated processes of division and fusion. Mitochondrial fission and fusion events enable energy demands to be met and provide mitochondrial quality control; disruption of these events in diabetes prevents elimination of damaged mitochondria and exacerbates ATP deficits (Forbes and Thorburn, 2018). Mitochondrial fusion is orchestrated by the long isoforms of optic atrophy protein 1 (OPA1), which primarily mediate inner mitochondrial membrane fusion, and the mitofusins (MFN1 and MFN2), responsible for outer mitochondrial membrane fusion (Mise et al., 2020; Ito et al., 2022). Conversely, mitochondrial division, known as fission, is facilitated by dynamin-1-like protein (DRP1) and its associated receptors such as FIS1, mitochondrial fission factor (MFF), and mitochondrial dynamics proteins of 49 and 51 kDa (MID49 and MID51). In the context of DKD, mitochondria, as dynamic components within cells, continually undergo both fission and fusion processes to adapt to changes in their environment. Fission is crucial for the creation of new mitochondria and the isolation of damaged ones, while fusion leads to the formation of elongated or tubular mitochondria, enabling the exchange of materials between them and potentially compensating for any functional impairments (Suárez-Rivero et al., 2017).
Excessive fission and reduced fusion in DKD
Imbalanced mitochondrial dynamics, characterized by excessive fission and reduced fusion, contribute to mitochondrial fragmentation in DKD, thus contributing to disease progression (Figure 4) (Yang et al., 2024) Fragmented mitochondria are more prone to dysfunction and apoptosis, further contributing to renal damage (Forbes and Thorburn, 2018). Even though there was an observed rise in mitochondrial fission and fusion factors like the long isoforms of OPA1, MFN1, MFN2, and MFF during the initial stages of DKD, mitochondria remained fragmented consistently from the early to late stages in rats injected with STZ (Ma et al., 2019). Human kidney biopsies from patients with DKD also revealed fragmented mitochondria in both podocytes and proximal tubular cells (Jiang et al., 2019; Ma et al., 2019). Consistent with increased fission and decreased fusion, DRP1 and FIS1 expression was increased, while MFN2 expression was shown to be decreased in tubules in the latter study (Ito et al., 2022). A-kinase anchoring protein (AKAP1) plays a pivotal role in the pathogenesis and progression of hyperglycemia (HG) -induced podocyte injury by disrupting mitochondrial dynamic homeostasis through the regulation of DRP1 phosphorylation in human podocytes (Chen Z. et al., 2020). Some findings indicate that upregulated expression of the thromboxane/prostaglandin (TP) receptor can be observed in a human cultured podocyte cell line, as well as in podocytes from streptozotocin (STZ)-induced diabetic mice. This upregulation contributes to mitochondrial excessive fission and podocyte injury through the activation of the Rho-associated kinase 1 (ROCK1)-DRP1 signaling pathway, promoting the phosphorylation of DRP1 at the Ser637 site (Liu S. et al., 2022). The lncRNA maternally expressed gene 3 (Meg3) contributes to podocyte injury induced by high glucose via increasing the levels of DRP1 and promoting its translocation to mitochondria (Deng et al., 2020). OMA1, a mitochondrial inner membrane zinc metalloprotease, is involved in the proteolysis of OPA1 when mitochondria are stressed, (Ehses et al., 2009), and glomerular OMA1 Zinc Metallopeptidase (OMA1) was activated in a time-dependent manner in DKD (Q et al., 2022). In addition, OMA1 activation-mediated hydrolysis of OPA1 participates in the mitochondrial fusion decrease of HG-induced podocyte (Q et al., 2022). In vitro experiments on HK2 cells, phosphoglycerate mutase family member 5 (PGAM5) exacerbates diabetic renal tubular injury, while AMPK activators mitigate DKD by rescuing the dephosphorylation of DRP1S637 and inhibiting the mitochondria-translocation of DRP1, that is to reduce mitochondrial fission through the AMPK/SP1/PGAM5 pathway (Liu et al., 2020).
Figure 4. Under hyperglycemia or diabetic disease environment, renal mitochondrial dynamics disorder. Drp1, dynamin-related protein 1; MFF, mitochondrial fission factor; ROCK1, Rho-associated kinase 1; TP, thromboxane receptor; AKAP1, a kinase-anchored protein 1; Meg3, maternally expressed gene 3; AMPK, adenosine monophosphate-activated protein kinase; PGAM5, phosphoglycerate mutase family member 5; Opa1, optic atrophy protein 1; Mfn1/2, mitochondrial fusion protein 1/2; FIs1, mitochondrial fission 1. Created with BioRender.com.
Mitochondrial mitophagy dysfunction
What is mitophagy?
Autophagy of damaged mitochondria, called mitophagy, is a crucial organelle quality control process that plays a significant role in the pathogenesis of inflammation, cancer, aging, and age-related diseases (Alula et al., 2023). The term “mitophagy” was first introduced in 2005, (Lemasters, 2005), and within a few years, major breakthroughs made the discovery of critical proteins that selectively mediate mitochondrial degradation (Schweers et al., 2007; Narendra et al., 2008; Sandoval et al., 2008). In mammals, mitophagy can occur through receptor-mediated or Ubiquitin-mediated manner (Onishi et al., 2021). The receptors encompass p62/sequestosome1 (SQSTM1), (Geisler et al., 2010), BCL2 interacting protein 3 (BNIP3), (Hanna et al., 2012), NIP3 like protein X (Nix/BNIP3L), (Novak et al., 2009), FUN14 domain containing 1 (FUNDC1), (Qi et al., 2012), B-cell lymphoma 2-like 13(BCL2L13), (Murakawa et al., 2015; 2019), FK506-binding protein 8 (FKBP8) (Bhujabal et al., 2017) and histone deacetylase 6 (HDAC6) (Lee et al., 2010). These receptor proteins have a special function that interacts with either mammalian Atg8 family members (LC3A/B/C, GABARAP, GABARAP-L1/2) via an microtubule-associated protein 1 light chain 3 (LC3) interacting region (LIR) or ubiquitin via an ubiquitin-binding domain (UBD) during mitophagy.
The ubiquitin-mediated manner in mitophagy: Parkin dependent or independent pathway
The PTEN-induced putative kinase 1 (PINK1)/Parkin-mediated pathway is the most studied mechanism of mitophagy (Figure 5) (Xiao et al., 2022). Dissipation of mitochondrial membrane potential (ΔΨm) is a potent trigger of mitophagy (Elmore et al., 2001). When the ΔΨm loss, PINK1 accumulates on the outer mitochondrial membrane (OMM) and phosphorylates pre-existing ubiquitin molecules at Ser65, recruiting Parkin (Okatsu et al., 2015; Wauer et al., 2015). PINK1 also phosphorylates the ubiquitin-like domain of Parkin, releasing its catalytic RING2 domain, which stabilizes Parkin in an active state. This leads to the ubiquitination of various OMM proteins, such as voltage-dependent anion channel (VDAC), mitochondrial rho GTPase (MIRO), MFN1, and MFN2 (Gladkova et al., 2018; Mitrofanova et al., 2022). These ubiquitinated proteins recruit mitophagy receptors including p62/SQSTM1, NBR1 autophagy cargo receptor (NBR1), calcium binding and coiled-coil domain 2 (NDP52), Tax1 binding protein 1 (TAX1BP1), and Optineurin (OPTN) and provide signals for Parkin-mediated mitochondrial degradation (Geisler et al., 2010; Jee and Cheong, 2023). In Parkin-independent pathway, PINK1-generated phospho-ubiquitin serves as the autophagy signal on mitochondria and PINK1 can directly recruit autophagy receptors OPTN and NDP52 to promote autophagy (Lazarou et al., 2015). This pathway can be used to compensate for the dysfunction of Parkin-mediated one.
Figure 5. Mitophagy pathways and several pathways regulating mitophagy in a hyperglycemic background. PINK1, PTEN-induced putative kinase 1; OMM, outer mitochondrial membrane; p62/SQSTM1, sequestosome 1; NBR1, NBR1 autophagy cargo receptor; NDP52, calcium binding and coiled-coil domain 2; TAX1BP1, Tax1 binding protein 1; OPTN, Optineurin; LC3, microtubule-associated protein 1 light chain 3; FKBP8, FK506-binding protein 8; FUNDC1, FUN14 domain containing 1; BNIP3, BCL2 interacting protein 3; Nix/BNIP3L, NIP3 like protein; PGAM5, phosphoglycerate mutase family member 5; ULK1, unc-51-like autophagy activating kinase 1; mTOR, mammalian target of rapamycin; AMPK, adenosine monophosphate-activated protein kinase; MFF, mitochondrial fission factor. Created with BioRender.com.
The receptor-mediated manner in mitophagy
In this section, we mainly discuss the receptor-mediated manner involving FUNDC1, BNIP3 and Nix (Figure 5). FUNDC1 contains a region interacting with LC3. In conditions such as hypoxia or loss of ΔΨm, FUNDC1 undergoes dephosphorylation at Tyr18 and Ser13 by PGAM5, while Ser17 is phosphorylated by unc-51-like autophagy activating kinase 1 (ULK1). This enhances the interaction between FUNDC1 and LC3, promoting mitophagy. PGAM5 activity is regulated by BCL2-like 1 (BCL-XL) (Wu et al., 2014). FUNDC1 interacts with two crucial regulators of mitochondrial dynamics: DRP1 and OPA1. This interaction allows FUNDC1 to coordinate both mitochondrial dynamics and mitophagy processes (Chen et al., 2016). BNIP3 and Nix, located on the outer mitochondrial membrane, are implicated in stress detection and hypoxia-triggered mitophagy (Zhang and Ney, 2009). Accumulation of ROS (induced by ROS) promotes Nix-mediated mitophagy via a recruitment of LC3 to mitochondria (Melser et al., 2013). Both BNIP3 and Nix interact with LC3 to enhance autophagosomal recruitment to mitochondria (Rogov et al., 2017).
Impaired mitophagy - A hallmark in DKD
Studies show that as kidney damage progresses in diabetes, ΔΨm decreases in the proximal tubule, (Coughlan et al., 2009; Tan et al., 2010; Forbes et al., 2013), endothelial cells (Qi H. et al., 2017) and podocytes (Qi W. et al., 2017). Podocytes have naturally high mitophagy levels due to maturity, while tubular cells show low baseline levels, increasing during stress (Ito et al., 2022). Inhibition of PINK1 distinctly increases albumin permeability and impairs the mitophagy function of podocytes (Audzeyenka et al., 2022). Impaired mitophagy is recognized as a hallmark of human DKD and of rodent models of DKD (Mitrofanova et al., 2022). In DKD patients and rats with STZ-induced DKD, high glucose levels activate thioredoxin-interacting protein (TXNIP) causing autophagosome accumulation and reduced autophagic clearance in tubular cells (Huang et al., 2016). High glucose-treated renal tubular epithelial cells and biopsies from DKD patients exhibit decreased mitophagy levels (Chen K. et al., 2018). Studies propose that glomerular endothelial cells exhibit decreased levels of LC3-II, PINK1, and Parkin when exposed to high glucose conditions, similar to findings observed in different types of kidney cells (Sun et al., 2019). In a rat model of STZ diabetes, in 4-week after diabetes induction (early diabetes), PINK1 was increased in the renal cortex (Smith et al., 2012). Diabetic db/db mice in 12-week period showed reduced expression of key mitophagy markers including mitochondrial PINK1, Parkin, LC3-II, Beclin-1, and Atg5, indicating impaired mitophagy (Feng et al., 2018). It is predictable that in early diabetes, the kidney activates mitophagy to satisfy the clearance of damaged mitochondria, but as DN progresses, leading to impairment of mitophagy and accumulation of fragmented mitochondria, even to death.
Regulation of mitophagy in hyperglycemic conditions
Several pathways regulating mitophagy in a hyperglycemic background are summarized here (Figure 5). Under physiological conditions when fuels are sufficient, AMPK activity is suppressed and mTOR inhibits ULK1, inhibiting mitophagy (Kim et al., 2011; Groenewoud and Zwartkruis, 2013). During nutrient deprivation, the increase of AMP/ATP ratio can activate AMPK and inhibit mTOR, phosphorylating the serine/threonine-protein kinase ULK1 and inducing mitophagy (Bhargava and Schnellmann, 2017). During oxidative stress, AMPK can be activated and inhibit mTOR, again triggering mitophagy (Groenewoud and Zwartkruis, 2013; Melser et al., 2013). A more direct role for AMPK to stimulate mitophagy has also been suggested. AMPK promotes DRP1 recruitment from cytosol to the OMM via mediating phosphorylation of MFF on its Ser155 and Ser172 sites (Ducommun et al., 2015; Toyama et al., 2016). Upon recruitment, DRP1 promotes the fission of mitochondria and subsequently enhances mitochondrial mitophagy (Toyama et al., 2016; Zhang and Lin, 2016). Evidences show that dysregulation of AMPK induced by elevated ROS level decreases mitochondrial function in the diabetic kidney (Dugan et al., 2013).
Hypoxia-induced mitophagy mechanisms
Other stimuli, such as hypoxia, cause PGAM5 to dephosphorylate its substrate FUNDC1 (Chen et al., 2014). FUNDC1 sequentially interacts with LC3, promoting mitophagy (Liu et al., 2012; Chen et al., 2014). Alternatively, hypoxia can also induce mitophagy through BNIP3 and Nix via hypoxia-inducible factor 1α (HIF1α) involving (Novak et al., 2009; Zhang and Ney, 2009). HIF1α can directly promote the transcription of BNIP3 and Nix by binding to BNIP3 promoter and recruiting other co-activator proteins to Nix. However, external stimuli that trigger mitophagy are unknown. Additional studies are needed to clarify the mechanisms that regulate mitophagy in DN.
Targeted treatment using pharmacological agents
As previously discussed, mitochondrial dysfunction is implicated in various aspects of DKD pathogenesis. Mitochondrial dysfunction can already manifest in the initial stages of hyperglycemia and is recognized as a key factor in the pathogenesis of DKD (Cleveland and Schnellmann, 2023). Despite the incomplete understanding of the precise role of mitochondrial function in DKD, improving mitochondrial dysfunction may be a very promising strategy for treatment of DKD (Yang et al., 2024). Emerging therapeutic approaches targeting mitochondrial dysfunction are currently being explored for the management of CKD. Data from preclinical studies indicate that these strategies may also hold promise for the treatment and prevention of DKD. We will discuss the specific strategies including targeting the redox state of mitochondria, mitochondrial biogenesis and ATP synthesis activators, fission inhibitors, and mitophagy inducers (Table 1).
Table 1. Mitochondria-targeted therapeutics.
Targeting the redox state of mitochondria
The clinical efficacy of quinone antioxidants in mitochondrial diseases: limited effect despite preclinical rationale
Oxidative stress is an important component in the development of DKD. Quinone-based antioxidants, encompassing CoQ analogs idebenone and EPI-743, (vatiquinone, vincerinone) alongside KH176, are employed as a frontline pharmacological agents against mitochondrial oxidative stress. Coenzyme Q10 (CoQ10, ubiquinone) is a component of the mitochondrial respiratory chain with antioxidant propertiy. CoQ10 is renoprotective and prevents damaging changes in mitochondrial function and morphology in rodent models of DKD (Sourris et al., 2012). CoQ10 has reached phase III clinical trials for mitochondrial disorders (University of Florida, 2017), but substantial benefits of the therapy have not been reported to date. Idebenone influences mitochondrial function acting as an antioxidant and directly transfers electrons to complex III bypassing complex I of the ETC (Jaber and Polster, 2015) This agent is already approved in Europe for indications such as Leber hereditary optic neuropathy, (Klopstock et al., 2013), but phase II and phase III clinical studies have not reached primary end points in other mitochondrial diseases (Lagedrost et al., 2011). EPI-743 enhancing glutathione biosynthesis has showed beneficial effects on mitochondrial diseases (Martinelli et al., 2012). In contrast, RP-103 (cysteamine bitartrate) has the function of enhancing the cellular supply of cysteine, which is thought to facilitate glutathione synthesis and has entered into phase II/III clinical trials in children with inherited mitochondrial diseases (Verny et al., 2017). KH-176, acting as a ROS-Redox modulator, is also thought to have antioxidant properties and can effectively increase the maximal efficiency of OXPHOS complexes I and IV by targeting the Thioredoxin/Peroxiredoxin system (Beyrath et al., 2018). This compound has completed pharmacokinetic studies and a phase I clinical trial (Koene et al., 2017). In the KHENERGY clinical trial, KH-176 shows no improvement in mitochondrial diseases (Khondrion, 2018).
Mitochondria-targeted antioxidants: a promising yet unproven therapeutic strategy for diabetic complications
Despite the promising potential of these agents, the efficacy of these antioxidants is constrained and clinical studies in patients with diabetic complications have been mostly disappointing (Forbes et al., 2008; Sorrentino et al., 2018). A probable explanation is that transport of these agents into the mitochondria, which is a highly lipophilic environment, is not sufficient to achieve efficacy or that the wrong mitochondrial is targeted. The advent of mitochondria-targeted antioxidants (e.g. Mitoquinone (MitoQ), (Graham et al., 2009), MitoTEMPO, MitoE, Mito-CP, SkQ1 (Petrov et al., 2016) and SkQR1) are attempts to reduce mitochondrial oxidative stress. Administration of MitoQ prevented DKD (Chacko et al., 2010) in a murine model of inherited diabetes and in experimental type 2 DM (T2DM) model (Ward et al., 2017). MitoQ was shown to be safe in clinical trial with Parkinson’s disease, fatty acid disease. The effect of MitoQ under clinical trial (NCT02364648) for CKD show no results posted. MitoTEMPO, improves podocyte injury by inhibiting the NLRP1 inflammasome and promoting the PINK3/Parkin pathway-mediated mitophagy (Liu B. et al., 2022). Szeto-Schiller (SS) peptide family (also known as MTP-131, SS-31, elamipretide or Bendavia) also could directly target cardiolipin peroxidation, independent to mitochondria membrane potential (Birk et al., 2013). MTP-131 passively diffusing into the mitochondria and residing in the IMM, has shown beneficial effects on function and fibrosis in acute kidney injury (AKI) studies involving ischaemic–reperfusion injury, models of experimental DN and unilateral ureteral obstruction (Q et al., 2022; Szeto et al., 2011; Birk et al., 2013). Further studies are needed to determine the effect of MitoQ and MTP-131 in human diabetic kidney disease. S1QELs and OP2113, inhibit ROS production without disturbing normal OXPHOS by targeting the complex I site (Brand et al., 2016; Roubenne et al., 2023). Curcumin (a derivative of turmeric) has an antioxidant effect via various pathways relevant to the development of DKD (Yang et al., 2015; Lu et al., 2017). In rat models of DKD, curcumin treatment shows modest improvements in renal function (Abd Allah and Gomaa, 2015). However, a pilot study showed no effects of curcumin treatment for 8 weeks on proteinuria and estimated GFR in patients with DKD (Jiménez-Osorio et al., 2016). Although mitochondria-targeted antioxidants may help reduce oxidative damage and repair lipid membranes, they may not restore functionality to damaged mitochondria.
Other experimental approaches have also been tested
Mitochonic acid 5 (MA-5), deriving from the plant growth hormone indole3-acetic acid, can protect mitochondrial function by regulating mitochondrial ATP synthesis and reducing the level of mitochondrial ROS without affecting activity of mitochondrial complexes I–IV (Suzuki et al., 2016; Lei et al., 2018). Astragaloside IV ameliorates mitochondrial dysfunction by upregulated Nrf2-ARE/TFAM signaling, then decreasing ROS production in mouse podocytes line (Shen et al., 2023). These agents, however, remain in their early stage of exploration.
Induction of mitochondrial biogenesis
Several pharmacological agents have been identified to have effects on these regulatory points, thereby enhancing mitochondrial biogenesis. Agents that promote mitochondrial biogenesis are an potential therapeutic strategy for DKD (Komen and Thorburn, 2014).
Targeting upstream sensor - AMPK
AMPK acts as an energy sensor of the cell and works as a key regulator of mitochondrial biogenesis. Pretreatment with AICAR, an AMPK activator, attenuated injury and tubular necrosis and improved renal function in a rat I/R induced AKI (Lempiäinen et al., 2012). Metformin, widely known for its role in diabetes management, specifically blocks the functioning of mitochondrial ETC complex I, bolsters mitochondrial biogenesis by subsequently activating AMPK, leading to an upsurge in PGC-1α expression and activation (Ota et al., 2009; Hawley et al., 2010; Aatsinki et al., 2014). Another study showed that melatonin (N-acetyl-5-methoxytryptamine) could also stimulate AMPK activity and PGC-1α expression to protect mice from diabetic kidney injury (Li et al., 2019). PXL770 is a clinical stage direct and specific allosteric AMPK activator and instigates mitochondrial biogenesis by acting as a direct stimulant of AMPK. In a preclinical investigation, PXL770 treatment restores mitochondrial DNA copy number and PGC-1α mRNA expression in mice with autosomal dominant polycystic kidney disease (ADPKD) (Dagorn et al., 2023). Nicotinamide riboside reveal SIRT2’s protective role in a diabetic-dietary rat model of NASH via deacetylation of NLRP3, LKB1, and FOXO3a and restoration of AMPK-ACC/PGC-1α-Nrf2 signaling (Hamad et al., 2025). Treatment of db/db mice with type 2 diabetes with nicotinamide riboside prevented several manifestations of kidney dysfunction (i.e., albuminuria, increased urinary kidney injury marker-1 (KIM1) excretion, and pathologic changes) (Myakala et al., 2023).
Targeting upstream sensor - SIRT1
PGC-1α is a marker of mitochondrial biogenesis and SIRT1 is known as an upstream activator of PGC-1α. Studies show downregulation of SIRT1 in podocytes and glomeruli in human diabetic kidneys as well as in diabetic mice (Chuang et al., 2007; Liu et al., 2014). Furthermore, selective pharmacological activation of SIRT1 in cultured podocytes increased SIRT1-mediated PGC-1α activity and protected cells from mitochondrial dysfunction resulting from hyperglycemic condition (Hong et al., 2018). Nihalani et al. showed that the β2-adrenergic receptor agonist Formoterol increases the expression of PGC-1α and multiple ETC proteins, promoting podocyte recovery after glomerular injury (Arif et al., 2019). Besides, β-Aminoisobutyric acid (L-BAIBA) upregulates PGC-1α and TFAM, promoting mitochondrial biogenesis and ameliorating podocyte injury (Audzeyenka et al., 2023).
Targeting downstream effecter - PPARγ
Studies has also shown that agonists of PPARγ stimulate mitochondrial biogenesis (Yang et al., 2009; Corona and Duchen, 2016). Bezafibrate and fenofibrate have been shown to target PPARα, which collaborates with PGC-1α to enhance mitochondrial biogenesis (Scarpulla, 2011). Thiazolidinediones, promote mitochondrial biogenesis by binding to and activating PPARs, which heterodimerize with Retinoid X Receptor (RXR) and bind to PPAR response elements in the DNA, thereby upregulating the transcription of genes involved in mitochondrial biogenesis (Bogacka et al., 2005).
Some natural products enhancing mitochondrial biogenesis
Multiple studies have explored natural products for their role to increase mitochondrial biogenesis. Puerarin, an isoflavonoid compound primarily from the roots of Pueraria lobata, significantly activates AMPK and upregulates the level of PGC-1α, thereby stimulating mitochondrial biogenesis (Chen X.-F. et al., 2018). Catalpol, an iridoid glycoside component, promotes mitochondrial biogenesis through activating the AMPK/PGC-1α/TFAM pathway (Xu et al., 2020). Gomisin N, a natural lignan compound primarily isolated from Schisandra chinensis, can upregulate genes linked to mitochondrial biogenesis, such as PGC-1α, TFAM, and NRF1, via phosphorylating AMPK and Protein kinase B (Akt) (Jung et al., 2017). Green tea extracts also increase PGC-1α and protect mice against cyclosporine-induced renal injury (Rehman et al., 2014). Catechins and their gallate esters constitute a group of polyphenolic compounds which include epicatechin, epicatechin gallate, epigallocatechin and epigallocatechin gallate (EGCG) (Farhan, 2022). EGCG increases the expression of PGC-1α at both mRNA and protein levels, leading to an increased mitochondrial biogenesis (Oliveira et al., 2016). Epicatechin, upregulates the expression of SIRT1, TFAM, and PGC-1α, resulting in increased mitochondrial biogenesis in mice and human coronary artery endothelial cells (Ramírez-Sánchez et al., 2016). Some other agents have also shown impacting PGC-1α activity via less clear mechanisms. For example, Salidroside, the active component of the Rhodiola rosea plant, and glycyrrhic acid from liquorice root both increase SIRT1 and PGC-1α and protect mice from DN (Xue et al., 2019; Hou et al., 2017). Many of the above species lack the necessary specificity for modulating PGC-1α. Treatment with sacubitril/valsartan (Sac/Val) improved mitochondrial function in maintaining mitochondrial biogenesis and fatty acid oxidation in db/db kidneys (Myakala et al., 2021). These compounds, through their action on specific targets, highlight the potential for pharmacological intervention to promote mitochondrial biogenesis in the context of mitochondrial dysfunction. Nevertheless, their clinical translation still requires further investigation.
Targeting mitochondrial dynamics
The imbalanced mitochondrial dynamics are associated with various diseases which are extensively characterized with deficiencies in mitochondrial function. It is demonstrated that improving mitochondrial health by modulating mitochondrial dynamics can reduce the risk of disease and promote overall wellbeing. Proteins involved in mitochondrial dynamics were altered in diabetic mice, favoring a pro-fission mitochondrial state in diabetic background (Cleveland et al., 2020). In recent years, research has made significant progresses in the discovery and development of effective inhibitors targeting mitochondrial fission.
Regulating mitochondrial fission
Mitochondrial division inhibitor specifically targets mitochondrial division proteins, selectively inhibiting the function of DRPs by interacting primarily with an orthosteric domain (Cassidy-Stone et al., 2008). Mdivi-1, as the initial inhibitor that specifically targets mitochondrial division proteins, can restore mitochondrial morphology in disease models characterized by excessive mitochondrial fission. As a small peptide, P110 specifically inhibits the interaction between FIS1 and DRP1, and suppresses mitochondrial fission process (Qi et al., 2013). DRP1i27, an inhibitor of human DRP1, binds to the GTPase domain of DRP1 by forming hydrogen bonds with Asp218 and Gln34 (Rosdah et al., 2022). Polydatin is resveratrol glycoside and is extracted from the radix of Polygonum cuspidatum. In conditionally immortalized mouse podocytes under high glucose condition, Polydatin attenuated mitochondrial fission by decreasing phosphorylation of DRP1 at Serine-616 (Ni et al., 2017). Administration of D-glucaric acid, which reduced ROS by inhibiting MIOX, to human (HK-2) and porcine (LLC-PK1) renal proximal tubular cells under diabetic background proved to attenuate renal mitochondrial fission, oxidative stress, while promoting the restoration of renal mitochondrial fusion (Zhan et al., 2015). Exenatide suppresses mitochondrial fission by phosphorylating DRP1 at Ser-637, thereby preventing the localization of DRP1within the mitochondria (Torres et al., 2016). Pretreatment of berberine in diabetic db/db mice significantly reverses elevated glucose, podocyte damage, and mesangial matrix expansion by inhibiting DRP1 activation (Qin et al., 2019). MitoQ protects podocytes against dysfunction and injury, such as Ang II-induced mitochondrial fission, by modulating the Keap1- NRF2 signaling pathway (Zhu et al., 2021). Several other small molecules, such as dynasore (Macia et al., 2006) and 1H-pyrrole-2-carboxamide compounds (Lim et al., 2020), have been reported to inhibit DRP1 and reduce mitochondrial fission. These newly identified molecules have demonstrated potential in preclinical research, but additional study is needed to evaluate their safety and efficacy in humans.
Regulating mitochondrial fusion
Chemical therapeutics have demonstrated potential in restoring abnormal mitochondrial dynamics by promoting and regulating the mitochondrial fusion machinery. However, there is a lack of reported small molecule compounds that directly affect mitochondrial fusion proteins. These small molecule compounds promote mitochondrial fusion via OPA1-mediated upregulating MFN1/2 expression or stimulating OPA1 mechanism. These compounds include enzyme (HO-1), (Hull et al., 2016), Melatonin, (Pei et al., 2016), M1, (Wang et al., 2012), 15-oxospiramilactone (S3) (Yue et al., 2014) in the former category and Punicalagin, (Fu et al., 2021), κ-opioid receptor, (Wang et al., 2020), Paeonol (Liu et al., 2021) in the latter category.
Targeting mitophagy
Numerous drugs have been reported that they can improve mitophagy dysfunction. Melatonin has been demonstrated to increase phosphorylation of Akt and NF-κ B, which subsequently activates PINK1-dependent protective mitophagy. Additionally, melatonin may upregulate NRF2-induced mitophagy to protect neuron in subarachnoid haemorrhage (SAH) against apoptosis (Sun et al., 2018). Pioglitazone, an anti-diabetic drug for T2DM in the category of thiazolidinediones (TZDs), boots PINK1 expression via NF-κ B activation and promotes mitophagy (Yoon et al., 2018). Rapamycin, a compound approved by the FDA, promotes Parkin/PINK1 mitophagy, probably via p62, to restore mitochondrial homeostasis (Wang et al., 2018). Metformin, an mTOR inhibitor, promotes mitophagy through various signaling pathways, including the AMPK- NRF2 as well as SIRT3 pathway (Wang C, et al., 2018; Chen L. et al., 2020). Recent randomized controlled clinical trials have demonstrated its potential to enhance mitophagy in T2DM (Wang C. et al., 2018). Spermidine induces mitophagy via ATM-dependent Parkin/PINK1 pathway, which modulate of the mTOR axis (Qi et al., 2016). Salidroside, a plant extract, has been demonstrated to protect dopamine (DA) neurons in Parkinson’s disease (PD) models by enhancing mitophagy. The underlying mechanism is likely linked to its bioactive effects on DJ-1/NRF2 pathway (Li and Chen, 2019). Honokiol, an agonist of SIRT3, promotes mitophagy and mitochondrial dynamics in vitro in an SIRT3-dependent manner via the AMPK/PGC-1α signaling pathway, and its neuroprotection has been validated in vivo (Wang J. et al., 2018). Gui et al. reported that Astragaloside II ameliorates podocyte injury and mitophagy dysfunction in diabetic rats by enhancing the expression NRF2 and PINK1 (Su et al., 2021). Sun et al. discovered that the Src inhibitor PP2 inhibits the phosphorylation of FUNDC1and promotes mitophagy, thereby protecting podocytes from mitochondrial damage (Zheng et al., 2022). Additionally, MitoQ alleviates tubular injury in DKD via NRF2/PINK1 (Xiao et al., 2017). Moreover, because mitophagy is dependent on mitochondrial dynamics, it is reasonable that modulation of fission and fusion may target the process of mitophagy. Preclinical studies are required to investigate efficacy and possible adverse effects of these chemicals in DN.
However, despite the many available and promising options for recovering mitochondrial dysfunction in DKD or hyperglycemic background, a deeper understanding of the therapeutic mechanisms and more further researches of these components are necessary to achieve precise treatment of DKD.
Future research directions
On the therapeutic aspect, although we have demonstrated that improving mitochondrial function can delay the progression of DKD in some cellular or animal experiments, a deeper evaluation of its therapeutic efficacy and safety is still lacking, so there are no drugs targeting mitochondrial dysfunction in DKD yet. The journey from bench to bedside is full of challenges, including the clinical heterogeneity of mitochondrial disorders, the low clinical efficacy and the potential side effects of long-term pharmacological interventions. Concurrently, the necessity for the conception of highly precise therapies becomes increasingly evident and urgent. Future studies should prioritize: (1) conducting large-scale clinical trials to evaluate mitochondrial-targeted therapies, focusing on patient-centered outcomes; (2) mitochondrial transplantation is another strategy burgeoning on therapeutic innovation. While most studies reported favorable results after mitochondrial transplantation, validation of the underlying mechanisms pertinent to its clinical translation remains an open challenge; (Hayashida et al., 2021); (3) developing biomarkers for mitochondrial dysfunction to guide personalized treatment; and (4) exploring combination therapies (e.g., SGLT2 inhibitors with mitophagy inducers) to enhance efficacy while minimizing off-target effects. Addressing these gaps will accelerate the translation of mitochondrial therapies into clinical practice.
Conclusion and perspective
In conclusion, mitochondrial dysfunction constitutes a cornerstone in the pathogenesis of DKD, with multifaceted mechanisms including impaired biogenesis, dysregulated mitophagy, altered fission-fusion dynamics, increased inflammation, altered OXPHOS, and mitochondrial DNA (mtDNA) damage. Understanding these intricate pathways provides crucial insights into potential therapeutic avenues.
Addressing mitochondrial dysfunction in DKD involves a comprehensive approach targeting various aspects of mitochondrial biology. Lifestyle modifications, encompassing regular exercise and dietary adjustments, present promising avenues to alleviate mitochondrial dysfunction and curb DKD progression. Moreover, timely interventions directed at restoring mitochondrial homeostasis through pharmacotherapy, focusing on mitigating oxidative stress and preserving mitochondrial dynamics, offer additional treatment modalities.
However, the complexity of mitochondrial involvement in DKD warrants further investigation to delineate precise mechanisms and develop targeted therapeutic strategies. Future research endeavors should explore innovative approaches aimed at preserving mitochondrial function and alleviating DKD burden, ultimately advancing the management and prognosis of this debilitating condition.
Author contributions
ZF: Writing – original draft. PL: Writing – original draft. YG: Writing – review and editing. HM: Writing – review and editing. JF: Writing – review and editing. SS: Writing – original draft. PZ: Writing – review and editing. KL: Writing – review and editing. HX: Writing – original draft.
Funding
The authors declare that financial support was received for the research and/or publication of this article. The study was supported by the National Natural Science Foundation of China (Grant No. 82204999 and 82274432), Scientific Research Fund Project of Zhejiang Administration of Traditional Chinese Medicine (Grant No. 2022ZB103 and 2021ZB093), Zhejiang Medical and Health Science and Technology Program Project (Grant No. 2022KY925).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The authors declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Aatsinki, S.-M., Buler, M., Salomäki, H., Koulu, M., Pavek, P., and Hakkola, J. (2014). Metformin induces PGC-1α expression and selectively affects hepatic PGC-1α functions. Br. J. Pharmacol. 171, 2351–2363. doi:10.1111/bph.12585
Abd Allah, E. S. H., and Gomaa, A. M. S. (2015). Effects of curcumin and captopril on the functions of kidney and nerve in streptozotocin-induced diabetic rats: role of angiotensin converting enzyme 1. Appl. Physiol. Nutr. Metab. 40, 1061–1067. doi:10.1139/apnm-2015-0145
Akhtar, S., and Siragy, H. M. (2019). Pro-renin receptor suppresses mitochondrial biogenesis and function via AMPK/SIRT-1/PGC-1α pathway in diabetic kidney. PLoS One 14, e0225728. doi:10.1371/journal.pone.0225728
Al-Kafaji, G., Sabry, M. A., and Skrypnyk, C. (2016). Time-course effect of high-glucose-induced reactive oxygen species on mitochondrial biogenesis and function in human renal mesangial cells. Cell Biol. Int. 40, 36–48. doi:10.1002/cbin.10520
Alicic, R. Z., Rooney, M. T., and Tuttle, K. R. (2017). Diabetic kidney disease: challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. 12, 2032–2045. doi:10.2215/CJN.11491116
Alula, K. M., Delgado-Deida, Y., Callahan, R., Till, A., Underwood, L., Thompson, W. E., et al. (2023). Inner mitochondrial membrane protein prohibitin 1 mediates Nix-induced, Parkin-independent mitophagy. Sci. Rep. 13, 18. doi:10.1038/s41598-022-26775-x
Amorim, R. G., Guedes, G. d. S., Vasconcelos, S. M. d. L., and Santos, J. C. d. F. (2019). Kidney disease in diabetes mellitus: cross-linking between hyperglycemia, redox imbalance and inflammation. Arq. Bras. Cardiol. 112, 577–587. doi:10.5935/abc.20190077
Arif, E., Solanki, A. K., Srivastava, P., Rahman, B., Fitzgibbon, W. R., Deng, P., et al. (2019). Mitochondrial biogenesis induced by the β2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. Kidney Int. 96, 656–673. doi:10.1016/j.kint.2019.03.023
Audzeyenka, I., Rachubik, P., Typiak, M., Kulesza, T., Kalkowska, D., Rogacka, D., et al. (2022). PTEN-induced kinase 1 deficiency alters albumin permeability and insulin signaling in podocytes. J. Mol. Med. Berl. 100, 903–915. doi:10.1007/s00109-022-02204-4
Audzeyenka, I., Szrejder, M., Rogacka, D., Angielski, S., Saleem, M. A., and Piwkowska, A. (2023). β-aminoisobutyric acid (L-BAIBA) is a novel regulator of mitochondrial biogenesis and respiratory function in human podocytes. Sci. Rep. 13, 766. doi:10.1038/s41598-023-27914-8
Beyrath, J., Pellegrini, M., Renkema, H., Houben, L., Pecheritsyna, S., Zandvoort, P. v., et al. (2018). KH176 safeguards mitochondrial diseased cells from redox stress-induced cell death by interacting with the thioredoxin system/peroxiredoxin enzyme machinery. Sci. Rep. 8, 6577. doi:10.1038/s41598-018-24900-3
Bhargava, P., and Schnellmann, R. G. (2017). Mitochondrial energetics in the kidney. Nat. Rev. Nephrol. 13, 629–646. doi:10.1038/nrneph.2017.107
Bhujabal, Z., Birgisdottir, Å. B., Sjøttem, E., Brenne, H. B., Øvervatn, A., Habisov, S., et al. (2017). FKBP8 recruits LC3A to mediate Parkin-independent mitophagy. EMBO Rep. 18, 947–961. doi:10.15252/embr.201643147
Birk, A. V., Liu, S., Soong, Y., Mills, W., Singh, P., Warren, J. D., et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J. Am. Soc. Nephrol. 24, 1250–1261. doi:10.1681/ASN.2012121216
Bogacka, I., Xie, H., Bray, G. A., and Smith, S. R. (2005). Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54, 1392–1399. doi:10.2337/diabetes.54.5.1392
Brand, M. D., Goncalves, R. L. S., Orr, A. L., Vargas, L., Gerencser, A. A., Borch Jensen, M., et al. (2016). Suppressors of superoxide-H2O2 production at site IQ of mitochondrial complex I protect against stem cell hyperplasia and ischemia-reperfusion injury. Cell Metab. 24, 582–592. doi:10.1016/j.cmet.2016.08.012
Bugger, H., Chen, D., Riehle, C., Soto, J., Theobald, H. A., Hu, X. X., et al. (2009). Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic akita mice. Diabetes 58, 1986–1997. doi:10.2337/db09-0259
Cassidy-Stone, A., Chipuk, J. E., Ingerman, E., Song, C., Yoo, C., Kuwana, T., et al. (2008). Chemical inhibition of the mitochondrial division dynamin reveals its role in bax/bak-dependent mitochondrial outer membrane permeabilization. Dev. Cell 14, 193–204. doi:10.1016/j.devcel.2007.11.019
Chacko, B. K., Reily, C., Srivastava, A., Johnson, M. S., Ye, Y., Ulasova, E., et al. (2010). Prevention of diabetic nephropathy in Ins2(+/)−(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem. J. 432, 9–19. doi:10.1042/BJ20100308
Chen, G., Han, Z., Feng, D., Chen, Y., Chen, L., Wu, H., et al. (2014). A regulatory signaling loop comprising the PGAM5 phosphatase and CK2 controls receptor-mediated mitophagy. Mol. Cell 54, 362–377. doi:10.1016/j.molcel.2014.02.034
Chen, M., Chen, Z., Wang, Y., Tan, Z., Zhu, C., Li, Y., et al. (2016). Mitophagy receptor FUNDC1 regulates mitochondrial dynamics and mitophagy. Autophagy 12, 689–702. doi:10.1080/15548627.2016.1151580
Chen, L., Liao, F., Jiang, Z., Zhang, C., Wang, Z., Luo, P., et al. (2020). Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy. Br. J. Pharmacol. 177, 3991–4006. doi:10.1111/bph.15149
Chen, Z., Ma, Y., Yang, Q., Hu, J., Feng, J., Liang, W., et al. (2020). AKAP1 mediates high glucose-induced mitochondrial fission through the phosphorylation of Drp1 in podocytes. J. Cell Physiol. 235, 7433–7448. doi:10.1002/jcp.29646
Chen, Y., Yang, Y., Liu, Z., and He, L. (2022). Adiponectin promotes repair of renal tubular epithelial cells by regulating mitochondrial biogenesis and function. Metabolism 128, 154959. doi:10.1016/j.metabol.2021.154959
Chen, W., Zhao, H., and Li, Y. (2023). Mitochondrial dynamics in health and disease: mechanisms and potential targets. Sig Transduct. Target Ther. 8, 1–25. doi:10.1038/s41392-023-01547-9
Chen, K., Dai, H., Yuan, J., Chen, J., Lin, L., Zhang, W., et al. (2018). Optineurin-mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy. Cell Death Dis. 9, 105. doi:10.1038/s41419-017-0127-z
Chen, X.-F., Wang, L., Wu, Y.-Z., Song, S.-Y., Min, H.-Y., Yang, Y., et al. (2018). Effect of puerarin in promoting fatty acid oxidation by increasing mitochondrial oxidative capacity and biogenesis in skeletal muscle in diabetic rats. Nutr. Diabetes 8, 1. doi:10.1038/s41387-017-0009-6
Chuang, P. Y., Yu, Q., Fang, W., Uribarri, J., and He, J. C. (2007). Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 72, 965–976. doi:10.1038/sj.ki.5002456
Clark, A. J., and Parikh, S. M. (2021). Targeting energy pathways in kidney disease: the roles of sirtuins, AMPK, and PGC1α. Kidney Int. 99, 828–840. doi:10.1016/j.kint.2020.09.037
Cleveland, K. H., and Schnellmann, R. G. (2023). Pharmacological targeting of mitochondria in diabetic kidney disease. Pharmacol. Rev. 75, 250–262. doi:10.1124/pharmrev.122.000560
Cleveland, K. H., Brosius, F. C., and Schnellmann, R. G. (2020). Regulation of mitochondrial dynamics and energetics in the diabetic renal proximal tubule by the β2-adrenergic receptor agonist formoterol. Am. J. Physiol. Ren. Physiol. 319, F773–F779. doi:10.1152/ajprenal.00427.2020
Corona, J. C., and Duchen, M. R. (2016). PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic. Biol. Med. 100, 153–163. doi:10.1016/j.freeradbiomed.2016.06.023
Coughlan, M. T., Thorburn, D. R., Penfold, S. A., Laskowski, A., Harcourt, B. E., Sourris, K. C., et al. (2009). RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 20, 742–752. doi:10.1681/ASN.2008050514
Coughlan, M. T., Higgins, G. C., Nguyen, T.-V., Penfold, S. A., Thallas-Bonke, V., Tan, S. M., et al. (2016a). Deficiency in apoptosis-inducing factor recapitulates chronic kidney disease via aberrant mitochondrial homeostasis. Diabetes 65, 1085–1098. doi:10.2337/db15-0864
Coughlan, M. T., Nguyen, T.-V., Penfold, S. A., Higgins, G. C., Thallas-Bonke, V., Tan, S. M., et al. (2016b). Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin. Sci. 130, 711–720. doi:10.1042/CS20150838
Dagorn, P. G., Buchholz, B., Kraus, A., Batchuluun, B., Bange, H., Blockken, L., et al. (2023). A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of autosomal dominant polycystic kidney disease. Kidney Int. 103, 917–929. doi:10.1016/j.kint.2023.01.026
Deng, Q., Wen, R., Liu, S., Chen, X., Song, S., Li, X., et al. (2020). Increased long noncoding RNA maternally expressed gene 3 contributes to podocyte injury induced by high glucose through regulation of mitochondrial fission. Cell Death Dis. 11, 814. doi:10.1038/s41419-020-03022-7
Ducommun, S., Deak, M., Sumpton, D., Ford, R. J., Núñez Galindo, A., Kussmann, M., et al. (2015). Motif affinity and mass spectrometry proteomic approach for the discovery of cellular AMPK targets: identification of mitochondrial fission factor as a new AMPK substrate. Cell Signal 27, 978–988. doi:10.1016/j.cellsig.2015.02.008
Dugan, L. L., You, Y.-H., Ali, S. S., Diamond-Stanic, M., Miyamoto, S., DeCleves, A.-E., et al. (2013). AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J. Clin. Invest 123, 4888–4899. doi:10.1172/JCI66218
Ehses, S., Raschke, I., Mancuso, G., Bernacchia, A., Geimer, S., Tondera, D., et al. (2009). Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. J. Cell Biol. 187, 1023–1036. doi:10.1083/jcb.200906084
Elmore, S. P., Qian, T., Grissom, S. F., and Lemasters, J. J. (2001). The mitochondrial permeability transition initiates autophagy in rat hepatocytes. FASEB J. 15, 2286–2287. doi:10.1096/fj.01-0206fje
Farhan, M. (2022). Green tea catechins: nature’s way of preventing and treating cancer. Int. J. Mol. Sci. 23, 10713. doi:10.3390/ijms231810713
Feng, J., Lu, C., Dai, Q., Sheng, J., and Xu, M. (2018). SIRT3 facilitates amniotic fluid stem cells to repair diabetic nephropathy through protecting mitochondrial homeostasis by modulation of mitophagy. Cell Physiol. Biochem. 46, 1508–1524. doi:10.1159/000489194
Fernandez-Marcos, P. J., and Auwerx, J. (2011). Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. Am. J. Clin. Nutr. 93, 884S–890S. doi:10.3945/ajcn.110.001917
Forbes, J. M., and Thorburn, D. R. (2018). Mitochondrial dysfunction in diabetic kidney disease. Nat. Rev. Nephrol. 14, 291–312. doi:10.1038/nrneph.2018.9
Forbes, J. M., Coughlan, M. T., and Cooper, M. E. (2008). Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57, 1446–1454. doi:10.2337/db08-0057
Forbes, J. M., Ke, B.-X., Nguyen, T.-V., Henstridge, D. C., Penfold, S. A., Laskowski, A., et al. (2013). Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease. Antioxid. Redox Signal 19, 331–343. doi:10.1089/ars.2012.4719
Fu, F., Liu, C., Shi, R., Li, M., Zhang, M., Du, Y., et al. (2021). Punicalagin protects against diabetic cardiomyopathy by promoting Opa1-mediated mitochondrial fusion via regulating PTP1B-Stat3 pathway. Antioxid. Redox Signal 35, 618–641. doi:10.1089/ars.2020.8248
Gao, H., and Wu, H. (2022). Maslinic acid activates renal AMPK/SIRT1 signaling pathway and protects against diabetic nephropathy in mice. BMC Endocr. Disord. 22, 25. doi:10.1186/s12902-022-00935-6
Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., et al. (2010). PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 12, 119–131. doi:10.1038/ncb2012
Geraldes, P., and King, G. L. (2010). Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res. 106, 1319–1331. doi:10.1161/CIRCRESAHA.110.217117
Ghose, S., Satariano, M., Korada, S., Cahill, T., Shah, R., and Raina, R. (2024). Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development. Am. J. Physiol. Endocrinol. Metab. 326, E791–E806. doi:10.1152/ajpendo.00026.2024
Gladkova, C., Maslen, S. L., Skehel, J. M., and Komander, D. (2018). Mechanism of Parkin activation by PINK1. Nature 559, 410–414. doi:10.1038/s41586-018-0224-x
Graham, D., Huynh, N. N., Hamilton, C. A., Beattie, E., Smith, R. A. J., Cochemé, H. M., et al. (2009). Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 54, 322–328. doi:10.1161/HYPERTENSIONAHA.109.130351
Groenewoud, M. J., and Zwartkruis, F. J. T. (2013). Rheb and mammalian target of rapamycin in mitochondrial homoeostasis. Open Biol. 3, 130185. doi:10.1098/rsob.130185
Guo, K., Lu, J., Huang, Y., Wu, M., Zhang, L., Yu, H., et al. (2015). Protective role of PGC-1α in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling. PLoS One 10, e0125176. doi:10.1371/journal.pone.0125176
Hamad, R. S., Hasan, W. A., Elmorsy, E. A., Farrag, A. A., Abdelaziz, M. A., Alalawy, A. I., et al. (2025). AGK2 and nicotinamide riboside reveal SIRT2’s protective role in a diabetic-dietary rat model of NASH via deacetylation of NLRP3, LKB1, and FOXO3a and restoration of AMPK-ACC/PGC-1α-Nrf2 signaling. Int. Immunopharmacol. 168, 115852. doi:10.1016/j.intimp.2025.115852
Hanna, R. A., Quinsay, M. N., Orogo, A. M., Giang, K., Rikka, S., and Gustafsson, Å. B. (2012). Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. J. Biol. Chem. 287, 19094–19104. doi:10.1074/jbc.M111.322933
Hawley, S. A., Ross, F. A., Chevtzoff, C., Green, K. A., Evans, A., Fogarty, S., et al. (2010). Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 11, 554–565. doi:10.1016/j.cmet.2010.04.001
Hayashida, K., Takegawa, R., Shoaib, M., Aoki, T., Choudhary, R. C., Kuschner, C. E., et al. (2021). Mitochondrial transplantation therapy for ischemia reperfusion injury: a systematic review of animal and human studies. J. Transl. Med. 19, 214. doi:10.1186/s12967-021-02878-3
Honda, T., Hirakawa, Y., and Nangaku, M. (2019). The role of oxidative stress and hypoxia in renal disease. Kidney Res. Clin. Pract. 38, 414–426. doi:10.23876/j.krcp.19.063
Hong, Q., Zhang, L., Das, B., Li, Z., Liu, B., Cai, G., et al. (2018). Increased podocyte sirtuin-1 function attenuates diabetic kidney injury. Kidney Int. 93, 1330–1343. doi:10.1016/j.kint.2017.12.008
Hou, S., Zhang, T., Li, Y., Guo, F., and Jin, X. (2017). Glycyrrhizic acid prevents diabetic nephropathy by activating AMPK/SIRT1/PGC-1α signaling in db/db mice. J. Diabetes Res. 2017, 2865912. doi:10.1155/2017/2865912
Huang, C., Zhang, Y., Kelly, D. J., Tan, C. Y. R., Gill, A., Cheng, D., et al. (2016). Thioredoxin interacting protein (TXNIP) regulates tubular autophagy and mitophagy in diabetic nephropathy through the mTOR signaling pathway. Sci. Rep. 6, 29196. doi:10.1038/srep29196
Huang, Y., Chi, J., Wei, F., Zhou, Y., Cao, Y., and Wang, Y. (2020). Mitochondrial DNA: a new predictor of diabetic kidney disease. Int. J. Endocrinol. 2020, 3650937. doi:10.1155/2020/3650937
Hull, T. D., Boddu, R., Guo, L., Tisher, C. C., Traylor, A. M., Patel, B., et al. (2016). Heme oxygenase-1 regulates mitochondrial quality control in the heart. JCI Insight 1, e85817. doi:10.1172/jci.insight.85817
Ito, M., Gurumani, M. Z., Merscher, S., and Fornoni, A. (2022). Glucose- and non-glucose-induced mitochondrial dysfunction in diabetic kidney disease. Biomolecules 12, 351. doi:10.3390/biom12030351
Jaber, S., and Polster, B. M. (2015). Idebenone and neuroprotection: Antioxidant, pro-oxidant, or electron carrier? J. Bioenerg. Biomembr. 47, 111–118. doi:10.1007/s10863-014-9571-y
Jalgaonkar, M. P., Parmar, U. M., Kulkarni, Y. A., and Oza, M. J. (2022). SIRT1-FOXOs activity regulates diabetic complications. Pharmacol. Res. 175, 106014. doi:10.1016/j.phrs.2021.106014
Jee, S.-C., and Cheong, H. (2023). Autophagy/mitophagy regulated by ubiquitination: a promising pathway in cancer therapeutics. Cancers 15, 1112. doi:10.3390/cancers15041112
Jha, J. C., Banal, C., Chow, B. S. M., Cooper, M. E., and Jandeleit-Dahm, K. (2016). Diabetes and kidney disease: role of oxidative stress. Antioxid. Redox Signal 25, 657–684. doi:10.1089/ars.2016.6664
Jiang, H., Shao, X., Jia, S., Qu, L., Weng, C., Shen, X., et al. (2019). The mitochondria-targeted metabolic tubular injury in diabetic kidney disease. Cell. Physiol. Biochem. 52, 156–171. doi:10.33594/000000011
Jiménez-Osorio, A. S., García-Niño, W. R., González-Reyes, S., Álvarez-Mejía, A. E., Guerra-León, S., Salazar-Segovia, J., et al. (2016). The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J. Ren. Nutr. 26, 237–244. doi:10.1053/j.jrn.2016.01.013
Jin, Q., Liu, T., Qiao, Y., Liu, D., Yang, L., Mao, H., et al. (2023). Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols. Front. Immunol. 14, 1185317. doi:10.3389/fimmu.2023.1185317
Jung, D. Y., Kim, J.-H., Lee, H., and Jung, M. H. (2017). Antidiabetic effect of gomisin N via activation of AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 494, 587–593. doi:10.1016/j.bbrc.2017.10.120
Kanwar, Y. S., Sun, L., Xie, P., Liu, F.-Y., and Chen, S. (2011). A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu. Rev. Pathol. 6, 395–423. doi:10.1146/annurev.pathol.4.110807.092150
Khondrion, B, V. (2018). An exploratory, double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitochondrial disease. Clinicaltrials.gov. Available online at: https://clinicaltrials.gov/study/NCT02909400 (Accessed December 13, 2024).
Kim, J., Kundu, M., Viollet, B., and Guan, K.-L. (2011). AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132–141. doi:10.1038/ncb2152
Klopstock, T., Metz, G., Yu-Wai-Man, P., Büchner, B., Gallenmüller, C., Bailie, M., et al. (2013). Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy. Brain 136, e230. doi:10.1093/brain/aws279
Koene, S., Spaans, E., Van Bortel, L., Van Lancker, G., Delafontaine, B., Badilini, F., et al. (2017). KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers. Orphanet J. Rare Dis. 12, 163. doi:10.1186/s13023-017-0715-0
Komen, J. C., and Thorburn, D. R. (2014). Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models. Br. J. Pharmacol. 171, 1818–1836. doi:10.1111/bph.12413
Lagedrost, S. J., Sutton, M. S. J., Cohen, M. S., Satou, G. M., Kaufman, B. D., Perlman, S. L., et al. (2011). Idebenone in friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am. Heart J. 161, 639–645.e1. doi:10.1016/j.ahj.2010.10.038
Lazarou, M., Sliter, D. A., Kane, L. A., Sarraf, S. A., Wang, C., Burman, J. L., et al. (2015). The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 524, 309–314. doi:10.1038/nature14893
Lee, J.-Y., Nagano, Y., Taylor, J. P., Lim, K. L., and Yao, T.-P. (2010). Disease-causing mutations in Parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J. Cell Biol. 189, 671–679. doi:10.1083/jcb.201001039
Lei, Q., Tan, J., Yi, S., Wu, N., Wang, Y., and Wu, H. (2018). Mitochonic acid 5 activates the MAPK–ERK–yap signaling pathways to protect mouse microglial BV-2 cells against TNFα-induced apoptosis via increased Bnip3-related mitophagy. Cell Mol. Biol. Lett. 23, 14. doi:10.1186/s11658-018-0081-5
Lemasters, J. J. (2005). Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 8, 3–5. doi:10.1089/rej.2005.8.3
Lempiäinen, J., Finckenberg, P., Levijoki, J., and Mervaala, E. (2012). AMPK activator AICAR ameliorates ischaemia reperfusion injury in the rat kidney. Br. J. Pharmacol. 166, 1905–1915. doi:10.1111/j.1476-5381.2012.01895.x
Li, R., and Chen, J. (2019). Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy. Oxidative Med. Cell. Longev. 2019, 1–11. doi:10.1155/2019/9341018
Li, S.-Y., Park, J., Qiu, C., Han, S. H., Palmer, M. B., Arany, Z., et al. (2017). Increasing the level of peroxisome proliferator-activated receptor γ coactivator-1α in podocytes results in collapsing glomerulopathy. JCI Insight 2, e92930. doi:10.1172/jci.insight.92930
Li, J., Li, N., Yan, S., Lu, Y., Miao, X., Gu, Z., et al. (2019). Melatonin attenuates renal fibrosis in diabetic mice by activating the AMPK/PGC1α signaling pathway and rescuing mitochondrial function. Mol. Med. Rep. 19, 1318–1330. doi:10.3892/mmr.2018.9708
Lim, J. W., Lee, J., and Pae, A. N. (2020). Mitochondrial dysfunction and Alzheimer’s disease: prospects for therapeutic intervention. BMB Rep. 53, 47–55. doi:10.5483/BMBRep.2020.53.1.279
Liu, L., Feng, D., Chen, G., Chen, M., Zheng, Q., Song, P., et al. (2012). Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat. Cell Biol. 14, 177–185. doi:10.1038/ncb2422
Liu, R., Zhong, Y., Li, X., Chen, H., Jim, B., Zhou, M.-M., et al. (2014). Role of transcription factor acetylation in diabetic kidney disease. Diabetes 63, 2440–2453. doi:10.2337/db13-1810
Liu, X., Xu, C., Xu, L., Li, X., Sun, H., Xue, M., et al. (2020). Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway. Metabolism 111, 154334. doi:10.1016/j.metabol.2020.154334
Liu, C., Han, Y., Gu, X., Li, M., Du, Y., Feng, N., et al. (2021). Paeonol promotes Opa1-mediated mitochondrial fusion via activating the CK2α-Stat3 pathway in diabetic cardiomyopathy. Redox Biol. 46, 102098. doi:10.1016/j.redox.2021.102098
Liu, B., Wang, D., Cao, Y., Wu, J., Zhou, Y., Wu, W., et al. (2022a). MitoTEMPO protects against podocyte injury by inhibiting NLRP3 inflammasome via PINK1/Parkin pathway-mediated mitophagy. Eur. J. Pharmacol. 929, 175136. doi:10.1016/j.ejphar.2022.175136
Liu, S., Li, X., Wen, R., Chen, L., Yang, Q., Song, S., et al. (2022b). Increased thromboxane/prostaglandin receptors contribute to high glucose-induced podocyte injury and mitochondrial fission through ROCK1-Drp1 signaling. Int. J. Biochem. Cell Biol. 151, 106281. doi:10.1016/j.biocel.2022.106281
Lu, M., Yin, N., Liu, W., Cui, X., Chen, S., and Wang, E. (2017). Curcumin ameliorates diabetic nephropathy by suppressing NLRP3 inflammasome signaling. Biomed. Res. Int. 2017, 1516985. doi:10.1155/2017/1516985
Ma, Y., Chen, Z., Tao, Y., Zhu, J., Yang, H., Liang, W., et al. (2019). Increased mitochondrial fission of glomerular podocytes in diabetic nephropathy. Endocr. Connect. 8, 1206–1212. doi:10.1530/EC-19-0234
Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C., and Kirchhausen, T. (2006). Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 839–850. doi:10.1016/j.devcel.2006.04.002
Martinelli, D., Catteruccia, M., Piemonte, F., Pastore, A., Tozzi, G., Dionisi-Vici, C., et al. (2012). EPI-743 reverses the progression of the pediatric mitochondrial disease—genetically defined leigh syndrome. Mol. Genet. Metabolism 107, 383–388. doi:10.1016/j.ymgme.2012.09.007
Melser, S., Chatelain, E. H., Lavie, J., Mahfouf, W., Jose, C., Obre, E., et al. (2013). Rheb regulates mitophagy induced by mitochondrial energetic status. Cell Metab. 17, 719–730. doi:10.1016/j.cmet.2013.03.014
Mise, K., Galvan, D. L., and Danesh, F. R. (2020). Shaping up mitochondria in diabetic nephropathy. Kidney360 1, 982–992. doi:10.34067/kid.0002352020
Mitrofanova, A., Fontanella, A. M., Burke, G. W., Merscher, S., and Fornoni, A. (2022). Mitochondrial contribution to inflammation in diabetic kidney disease. Cells 11, 3635. doi:10.3390/cells11223635
Murakawa, T., Yamaguchi, O., Hashimoto, A., Hikoso, S., Takeda, T., Oka, T., et al. (2015). Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation. Nat. Commun. 6, 7527. doi:10.1038/ncomms8527
Murakawa, T., Okamoto, K., Omiya, S., Taneike, M., Yamaguchi, O., and Otsu, K. (2019). A mammalian mitophagy receptor, Bcl2-L-13, recruits the ULK1 complex to induce mitophagy. Cell Rep. 26, 338–345.e6. doi:10.1016/j.celrep.2018.12.050
Myakala, K., Jones, B. A., Wang, X. X., and Levi, M. (2021). Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment. Am. J. Physiology-Renal Physiology 320, F1133–F1151. doi:10.1152/ajprenal.00614.2020
Myakala, K., Wang, X. X., Shults, N. V., Krawczyk, E., Jones, B. A., Yang, X., et al. (2023). NAD metabolism modulates inflammation and mitochondria function in diabetic kidney disease. J. Biol. Chem. 299, 104975. doi:10.1016/j.jbc.2023.104975
Nabi, R., Alvi, S. S., Shah, A., Chaturvedi, C. P., Faisal, M., Alatar, A. A., et al. (2023). Ezetimibe attenuates experimental diabetes and renal pathologies via targeting the advanced glycation, oxidative stress and AGE-RAGE signalling in rats. Arch. Physiol. Biochem. 129, 831–846. doi:10.1080/13813455.2021.1874996
Narendra, D., Tanaka, A., Suen, D.-F., and Youle, R. J. (2008). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–803. doi:10.1083/jcb.200809125
Ni, Z., Tao, L., Xiaohui, X., Zelin, Z., Jiangang, L., Zhao, S., et al. (2017). Polydatin impairs mitochondria fitness and ameliorates podocyte injury by suppressing Drp1 expression. J. Cell Physiol. 232, 2776–2787. doi:10.1002/jcp.25943
Novak, I., Kirkin, V., McEwan, D. G., Zhang, J., Wild, P., Rozenknop, A., et al. (2009). Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep. 11, 45–51. doi:10.1038/embor.2009.256
Okatsu, K., Koyano, F., Kimura, M., Kosako, H., Saeki, Y., Tanaka, K., et al. (2015). Phosphorylated ubiquitin chain is the genuine Parkin receptor. J. Cell Biol. 209, 111–128. doi:10.1083/jcb.201410050
Oliveira, M. R. D., Nabavi, S. F., Daglia, M., Rastrelli, L., and Nabavi, S. M. (2016). Epigallocatechin gallate and mitochondria—a story of life and death. Pharmacol. Res. 104, 70–85. doi:10.1016/j.phrs.2015.12.027
Onishi, M., Yamano, K., Sato, M., Matsuda, N., and Okamoto, K. (2021). Molecular mechanisms and physiological functions of mitophagy. EMBO J. 40, e104705. doi:10.15252/embj.2020104705
Ota, S., Horigome, K., Ishii, T., Nakai, M., Hayashi, K., Kawamura, T., et al. (2009). Metformin suppresses glucose-6-phosphatase expression by a complex I inhibition and AMPK activation-independent mechanism. Biochem. Biophys. Res. Commun. 388, 311–316. doi:10.1016/j.bbrc.2009.07.164
Pei, H., Du, J., Song, X., He, L., Zhang, Y., Li, X., et al. (2016). Melatonin prevents adverse myocardial infarction remodeling via Notch1/Mfn2 pathway. Free Radic. Biol. Med. 97, 408–417. doi:10.1016/j.freeradbiomed.2016.06.015
Persson, M. F., Franzén, S., Catrina, S.-B., Dallner, G., Hansell, P., Brismar, K., et al. (2012). Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes. Diabetologia 55, 1535–1543. doi:10.1007/s00125-012-2469-5
Petrov, A., Perekhvatova, N., Skulachev, M., Stein, L., and Ousler, G. (2016). SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model. Adv. Ther. 33, 96–115. doi:10.1007/s12325-015-0274-5
Q, Y., W, X., X, W., J, L., Y, Z., H, C., et al. (2022). SS31 ameliorates podocyte injury via inhibiting OMA1-mediated hydrolysis of OPA1 in diabetic kidney disease. Front. Pharmacol. 12, 707006. doi:10.3389/fphar.2021.707006
Qi, Y., Tian, X., Liu, J., Han, Y., Graham, A. M., Simon, M. C., et al. (2012). Bnip3 and AIF cooperate to induce apoptosis and cavitation during epithelial morphogenesis. J. Cell Biol. 198, 103–114. doi:10.1083/jcb.201111063
Qi, X., Qvit, N., Su, Y.-C., and Mochly-Rosen, D. (2013). A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J. Cell Sci. 126, 789–802. doi:10.1242/jcs.114439
Qi, Y., Qiu, Q., Gu, X., Tian, Y., and Zhang, Y. (2016). ATM mediates spermidine-induced mitophagy via PINK1 and Parkin regulation in human fibroblasts. Sci. Rep. 6, 24700. doi:10.1038/srep24700
Qi, H., Casalena, G., Shi, S., Yu, L., Ebefors, K., Sun, Y., et al. (2017a). Glomerular endothelial mitochondrial dysfunction is essential and characteristic of diabetic kidney disease susceptibility. Diabetes 66, 763–778. doi:10.2337/db16-0695
Qi, W., Keenan, H. A., Li, Q., Ishikado, A., Kannt, A., Sadowski, T., et al. (2017b). Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat. Med. 23, 753–762. doi:10.1038/nm.4328
Qin, X., Zhao, Y., Gong, J., Huang, W., Su, H., Yuan, F., et al. (2019). Berberine protects glomerular podocytes via inhibiting Drp1-mediated mitochondrial fission and dysfunction. Theranostics 9, 1698–1713. doi:10.7150/thno.30640
Qiu, D., Song, S., Wang, Y., Bian, Y., Wu, M., Wu, H., et al. (2022). NAD(P)H: quinone oxidoreductase 1 attenuates oxidative stress and apoptosis by regulating Sirt1 in diabetic nephropathy. J. Transl. Med. 20, 44. doi:10.1186/s12967-021-03197-3
Ramírez-Sánchez, I., Rodríguez, A., Moreno-Ulloa, A., Ceballos, G., and Villarreal, F. (2016). (-)-epicatechin-induced recovery of mitochondria from simulated diabetes: potential role of endothelial nitric oxide synthase. Diab Vasc. Dis. Res. 13, 201–210. doi:10.1177/1479164115620982
Ratliff, B. B., Abdulmahdi, W., Pawar, R., and Wolin, M. S. (2016). Oxidant mechanisms in renal injury and disease. Antioxidants Redox Signal. 25, 119–146. doi:10.1089/ars.2016.6665
Rehman, H., Krishnasamy, Y., Haque, K., Thurman, R. G., Lemasters, J. J., Schnellmann, R. G., et al. (2014). Green tea polyphenols stimulate mitochondrial biogenesis and improve renal function after chronic cyclosporin a treatment in rats. PLoS One 8, e65029. doi:10.1371/journal.pone.0065029
Rogov, V. V., Suzuki, H., Marinković, M., Lang, V., Kato, R., Kawasaki, M., et al. (2017). Phosphorylation of the mitochondrial autophagy receptor Nix enhances its interaction with LC3 proteins. Sci. Rep. 7, 1131. doi:10.1038/s41598-017-01258-6
Rosdah, A. A., Abbott, B. M., Langendorf, C. G., Deng, Y., Truong, J. Q., Waddell, H. M. M., et al. (2022). A novel small molecule inhibitor of human Drp1. Sci. Rep. 12, 21531. doi:10.1038/s41598-022-25464-z
Roubenne, L., Laisné, M., Benoist, D., Campagnac, M., Prunet, B., Pasdois, P., et al. (2023). OP2113, a new drug for chronic hypoxia-induced pulmonary hypertension treatment in rat. Br. J. Pharmacol. 180, 2802–2821. doi:10.1111/bph.16174
Sakashita, M., Tanaka, T., and Inagi, R. (2021). Metabolic changes and oxidative stress in diabetic kidney disease. Antioxidants (Basel) 10, 1143. doi:10.3390/antiox10071143
San-Millán, I. (2023). The key role of mitochondrial function in health and disease. Antioxidants 12, 782. doi:10.3390/antiox12040782
Sandoval, H., Thiagarajan, P., Dasgupta, S. K., Schumacher, A., Prchal, J. T., Chen, M., et al. (2008). Essential role for nix in autophagic maturation of erythroid cells. Nature 454, 232–235. doi:10.1038/nature07006
Santos, J. M., Mohammad, G., Zhong, Q., and Kowluru, R. A. (2011). Diabetic retinopathy, superoxide damage and antioxidants. Curr. Pharm. Biotechnol. 12, 352–361. doi:10.2174/138920111794480507
Scarpulla, R. C. (2011). Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim. Biophys. Acta 1813, 1269–1278. doi:10.1016/j.bbamcr.2010.09.019
Schweers, R. L., Zhang, J., Randall, M. S., Loyd, M. R., Li, W., Dorsey, F. C., et al. (2007). NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc. Natl. Acad. Sci. U. S. A. 104, 19500–19505. doi:10.1073/pnas.0708818104
Shen, Q., Fang, J., Guo, H., Su, X., Zhu, B., Yao, X., et al. (2023). Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease. Free Radic. Biol. Med. 203, 45–57. doi:10.1016/j.freeradbiomed.2023.03.022
Smith, M. A., Covington, M. D., and Schnellmann, R. G. (2012). Loss of calpain 10 causes mitochondrial dysfunction during chronic hyperglycemia. Arch. Biochem. Biophys. 523, 161–168. doi:10.1016/j.abb.2012.04.020
Song, Y., Yu, H., Sun, Q., Pei, F., Xia, Q., Gao, Z., et al. (2022). Grape seed proanthocyanidin extract targets p66Shc to regulate mitochondrial biogenesis and dynamics in diabetic kidney disease. Front. Pharmacol. 13, 1035755. doi:10.3389/fphar.2022.1035755
Sorrentino, V., Menzies, K. J., and Auwerx, J. (2018). Repairing mitochondrial dysfunction in disease. Annu. Rev. Pharmacol. Toxicol. 58, 353–389. doi:10.1146/annurev-pharmtox-010716-104908
Sourris, K. C., Harcourt, B. E., Tang, P. H., Morley, A. L., Huynh, K., Penfold, S. A., et al. (2012). Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic. Biol. Med. 52, 716–723. doi:10.1016/j.freeradbiomed.2011.11.017
Su, J., Gao, C., Xie, L., Fan, Y., Shen, Y., Huang, Q., et al. (2021). Astragaloside II ameliorated podocyte injury and mitochondrial dysfunction in streptozotocin-induced diabetic rats. Front. Pharmacol. 12, 638422. doi:10.3389/fphar.2021.638422
Suárez-Rivero, J. M., Villanueva-Paz, M., De la Cruz-Ojeda, P., De la Mata, M., Cotán, D., Oropesa-Ávila, M., et al. (2017). Mitochondrial dynamics in mitochondrial diseases. 5, 1. doi:10.3390/diseases5010001
Sun, B., Yang, S., Li, S., and Hang, C. (2018). Melatonin upregulates nuclear factor erythroid-2 related factor 2 (Nrf2) and mediates mitophagy to protect against early brain injury after subarachnoid hemorrhage. Med. Sci. Monit. 24, 6422–6430. doi:10.12659/MSM.909221
Sun, J., Zhu, H., Wang, X., Gao, Q., Li, Z., and Huang, H. (2019). CoQ10 ameliorates mitochondrial dysfunction in diabetic nephropathy through mitophagy. J. Endocrinol. 240, 445–465. doi:10.1530/JOE-18-0578
Suzuki, T., Yamaguchi, H., Kikusato, M., Hashizume, O., Nagatoishi, S., Matsuo, A., et al. (2016). Mitochonic acid 5 binds mitochondria and ameliorates renal tubular and cardiac myocyte damage. J. Endocrinol. 27, 1925–1932. doi:10.1681/ASN.2015060623
Swan, E. J., Salem, R. M., Sandholm, N., Tarnow, L., Rossing, P., Lajer, M., et al. (2015). Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes. Diabet. Med. 32, 1104–1109. doi:10.1111/dme.12763
Szeto, H. H., Liu, S., Soong, Y., Wu, D., Darrah, S. F., Cheng, F.-Y., et al. (2011). Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J. Am. Soc. Nephrol. 22, 1041–1052. doi:10.1681/ASN.2010080808
Tan, A. L. Y., Sourris, K. C., Harcourt, B. E., Thallas-Bonke, V., Penfold, S., Andrikopoulos, S., et al. (2010). Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 298, F763–F770. doi:10.1152/ajprenal.00591.2009
Torres, G., Morales, P. E., García-Miguel, M., Norambuena-Soto, I., Cartes-Saavedra, B., Vidal-Peña, G., et al. (2016). Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation. Biochem. Pharmacol. 104, 52–61. doi:10.1016/j.bcp.2016.01.013
Toyama, E. Q., Herzig, S., Courchet, J., Lewis, T. L., Losón, O. C., Hellberg, K., et al. (2016). Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 351, 275–281. doi:10.1126/science.aab4138
University of Florida. (2017). Phase 3 trial of coenzyme Q10 in mitochondrial disease. clinicaltrials.gov. Available online at: https://clinicaltrials.gov/study/NCT00432744 (Accessed December 13, 2024).
Ventura-Clapier, R., Garnier, A., and Veksler, V. (2008). Transcriptional control of mitochondrial biogenesis: the Central Role of PGC-1alpha. Cardiovasc. Research 79, 208–217. doi:10.1093/cvr/cvn098
Verny, C., Bachoud-Lévi, A.-C., Durr, A., Goizet, C., Azulay, J.-P., Simonin, C., et al. (2017). A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington’s disease: trial evaluating cysteamine in HD. Mov. Disord. 32, 932–936. doi:10.1002/mds.27010
Wang, C., Yang, Y., Zhang, Y., Liu, J., Yao, Z., and Zhang, C. (2018). Protective effects of metformin against osteoarthritis through upregulation of SIRT3-mediated PINK1/Parkin-dependent mitophagy in primary chondrocytes. BST 12, 605–612. doi:10.5582/bst.2018.01263
Wang, D., Wang, J., Bonamy, G. M. C., Meeusen, S., Brusch, R. G., Turk, C., et al. (2012). A small molecule promotes mitochondrial fusion in mammalian cells. Angew. Chem. Int. Ed. 51, 9302–9305. doi:10.1002/anie.201204589
Wang, K., Liu, Z., Zhao, M., Zhang, F., Wang, K., Feng, N., et al. (2020). κ-opioid receptor activation promotes mitochondrial fusion and enhances myocardial resistance to ischemia and reperfusion injury via STAT3-OPA1 pathway. Eur. J. Pharmacol. 874, 172987. doi:10.1016/j.ejphar.2020.172987
Wang, J., Nisar, M., Huang, C., Pan, X., Lin, D., Zheng, G., et al. (2018). Small molecule natural compound agonist of SIRT3 as a therapeutic target for the treatment of intervertebral disc degeneration. Exp. Mol. Med. 50, 1–14. doi:10.1038/s12276-018-0173-3
Wang, Y., Tang, C., Cai, J., Chen, G., Zhang, D., Zhang, Z., et al. (2018). PINK1/Parkin-mediated mitophagy is activated in cisplatin nephrotoxicity to protect against kidney injury. Cell Death Dis. 9, 1113. doi:10.1038/s41419-018-1152-2
Ward, M. S., Flemming, N. B., Gallo, L. A., Fotheringham, A. K., McCarthy, D. A., Zhuang, A., et al. (2017). Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes. Sci. Rep. 7, 15190. doi:10.1038/s41598-017-15589-x
Wauer, T., Simicek, M., Schubert, A., and Komander, D. (2015). Mechanism of phospho-ubiquitin-induced PARKIN activation. Nature 524, 370–374. doi:10.1038/nature14879
Wei, P. Z., and Szeto, C. C. (2019). Mitochondrial dysfunction in diabetic kidney disease. Clin. Chim. Acta 496, 108–116. doi:10.1016/j.cca.2019.07.005
Wu, H., Xue, D., Chen, G., Han, Z., Huang, L., Zhu, C., et al. (2014). The BCL2L1 and PGAM5 axis defines hypoxia-induced receptor-mediated mitophagy. Autophagy 10, 1712–1725. doi:10.4161/auto.29568
Wu, L., Wang, Q., Guo, F., Zhou, Y., Ji, H., Liu, F., et al. (2015). Activation of FoxO1/PGC-1α prevents mitochondrial dysfunction and ameliorates mesangial cell injury in diabetic rats. Mol. Cell Endocrinol. 413, 1–12. doi:10.1016/j.mce.2015.06.007
Xiao, L., Xu, X., Zhang, F., Wang, M., Xu, Y., Tang, D., et al. (2017). The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1. Redox Biol. 11, 297–311. doi:10.1016/j.redox.2016.12.022
Xiao, B., Kuruvilla, J., and Tan, E.-K. (2022). Mitophagy and reactive oxygen species interplay in Parkinson’s disease. Npj Park. Dis. 8, 1–13. doi:10.1038/s41531-022-00402-y
Xu, D.-Q., Li, C.-J., Jiang, Z.-Z., Wang, L., Huang, H.-F., Li, Z.-J., et al. (2020). The hypoglycemic mechanism of catalpol involves increased AMPK-mediated mitochondrial biogenesis. Acta Pharmacol. Sin. 41, 791–799. doi:10.1038/s41401-019-0345-2
Xue, H., Li, P., Luo, Y., Wu, C., Liu, Y., Qin, X., et al. (2019). Salidroside stimulates the Sirt1/PGC-1α axis and ameliorates diabetic nephropathy in mice. Phytomedicine 54, 240–247. doi:10.1016/j.phymed.2018.10.031
Yang, H.-C., Deleuze, S., Zuo, Y., Potthoff, S. A., Ma, L.-J., and Fogo, A. B. (2009). The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J. Am. Soc. Nephrol. 20, 2380–2388. doi:10.1681/ASN.2008111138
Yang, H., Xu, W., Zhou, Z., Liu, J., Li, X., Chen, L., et al. (2015). Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. Exp. Clin. Endocrinol. Diabetes 123, 360–367. doi:10.1055/s-0035-1545345
Yang, Y., Liu, J., Shi, Q., Guo, B., Jia, H., Yang, Y., et al. (2024). Roles of mitochondrial dysfunction in diabetic kidney disease: new perspectives from mechanism to therapy. Biomolecules 14, 733. doi:10.3390/biom14060733
Ye, S., Zhang, M., Tang, S. C. W., Li, B., and Chen, W. (2024). PGC1-α in diabetic kidney disease: unraveling renoprotection and molecular mechanisms. Mol. Biol. Rep. 51, 304. doi:10.1007/s11033-024-09232-y
Yoon, Y. M., Han, Y.-S., Yun, C. W., Lee, J. H., Kim, R., and Lee, S. H. (2018). Pioglitazone protects mesenchymal stem cells against P-cresol-induced mitochondrial dysfunction via up-regulation of PINK-1. Int. J. Mol. Sci. 19, 2898. doi:10.3390/ijms19102898
Yue, W., Chen, Z., Liu, H., Yan, C., Chen, M., Feng, D., et al. (2014). A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30. Cell Res. 24, 482–496. doi:10.1038/cr.2014.20
Zhan, M., Usman, I. M., Sun, L., and Kanwar, Y. S. (2015). Disruption of renal tubular mitochondrial quality control by Myo-inositol oxygenase in diabetic kidney disease. J. Am. Soc. Nephrol. 26, 1304–1321. doi:10.1681/ASN.2014050457
Zhang, C.-S., and Lin, S.-C. (2016). AMPK promotes autophagy by facilitating mitochondrial fission. Cell Metab. 23, 399–401. doi:10.1016/j.cmet.2016.02.017
Zhang, J., and Ney, P. A. (2009). Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ. 16, 939–946. doi:10.1038/cdd.2009.16
Zhang, L., Liu, J., Zhou, F., Wang, W., and Chen, N. (2018a). PGC-1α ameliorates kidney fibrosis in mice with diabetic kidney disease through an antioxidative mechanism. Mol. Med. Rep. 17, 4490–4498. doi:10.3892/mmr.2018.8433
Zhang, Y., Feng, J., Wang, Q., Zhao, S., Yang, S., Tian, L., et al. (2018b). Hyperglycaemia stress-induced renal injury is caused by extensive mitochondrial fragmentation, attenuated MKP1 signalling, and activated JNK-CaMKII-Fis1 biological axis. Cell Physiol. Biochem. 51, 1778–1798. doi:10.1159/000495681
Zheng, T., Wang, H., Chen, Y., Chen, X., Wu, Z., Hu, Q., et al. (2022). Src activation aggravates podocyte injury in diabetic nephropathy via suppression of FUNDC1-mediated mitophagy. Front. Pharmacol. 13, 897046. doi:10.3389/fphar.2022.897046
Keywords: diabetic kidney disease, mitochondrial dysfunction, oxidative stress, therapeuticinterventions, mitochondrial biogenesis, clinical translation
Citation: Fan Z, Luo P, Gao Y, Ma H, Fan J, Sanan S, Zhang P, Lu K and Xia H (2026) Unraveling the role of mitochondrial dysfunction in diabetic kidney disease: insights and interventions. Front. Pharmacol. 16:1618418. doi: 10.3389/fphar.2025.1618418
Received: 26 April 2025; Accepted: 24 November 2025;
Published: 06 January 2026.
Edited by:
Komuraiah Myakala, Georgetown University Medical Center, United StatesReviewed by:
Anjali Srivastava, Indian Council of Medical Research (ICMR), IndiaSanya Arshad, University of Pittsburgh, United States
Copyright © 2026 Fan, Luo, Gao, Ma, Fan, Sanan, Zhang, Lu and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hong Xia, eGlhaG9uZ2FpbmlAMTI2LmNvbQ==; Keda Lu, THVrZWRhcUAxMjYuY29t; Peipei Zhang, emhhbmdwZWlwZWluanVAaG90bWFpbC5jb20=
†These authors have contributed equally to this work